{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:37Z","timestamp":1794047557875,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Excellent outcomes of HLA identical related donor hematopoietic stem cell transplant (HSCT) in patients with sickle cell disease (SCD) have put it as a standard of care in symptomatic patients especially after a failed hydroxyurea therapy, however a large part of this data comes from resourcerich settings. These encouraging outcomes are in-turn due to patients being considered for HSCT in relatively well-preserved condition, safer transplant conditioning, better GvHD prophylaxis strategies and improved overall supportive care. Large-scale real-world data from resource-constraint settings is however missing. We retrospectively analysed baseline characteristics and longitudinal data of 85 paediatric and young adults who underwent matched sibling donor (MSD) HSCT for SCD over a decade. Patients received conditioning as per APOLLO PROTOCOL from May 2019. Median age was 8 years (range 10 months \u2013 32 years). Median time to neutrophil and platelet engraftment was 13 days (range, 10-19) and 14 days (range, 6-48). None experienced primary graft failure and one had secondary graft failure. Acute GvHD was seen in 5 patients (4- acute skin GvHD, grade I\/II; 1- gut GvHD, grade IV). At a median follow up of 1191 days (range, 23\u20134226), Kaplan Meier estimated EFS and OS is 94.11% and 96.47% respectively. OS in APOLLO protocol cohort was 100% and 91.4% using conventional (BU-CY or TTF based conditioning). Age &gt; 10 years turned out to be the only significant risk factor affecting outcome (100% vs 89.28%, P=0.007). This emphasizes the need of early intervention &lt; 10 years of age for best clinical outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2026.300729","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:37:03Z","timestamp":1778744223000},"source":"Crossref","is-referenced-by-count":1,"title":["Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease"],"prefix":"10.3324","author":[{"given":"Gaurav","family":"Kharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Nirmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaprakash","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eby","family":"Baby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Bakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetlana","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Chowdhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathymon","family":"Kuttappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himshikha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,5,14]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14180\/80291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14180\/80291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:13Z","timestamp":1794046453000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.300729","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}